All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

DONATE

Brought to you by

Scientific Education Support logo

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

SubtypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2020-02-27T16:21:06.000Z

NICE recommends lenalidomide in combination with rituximab for patients with previously treated FL

By Claire Baker
Feb 27, 2020
Share:

Bookmark this article

A novel combination therapy has been made available on the NHS for patients with previously treated follicular lymphoma (FL; Grade 1 –3A). In the final appraisal document, the National Institute for Care Excellence (NICE) recommended the combination of lenalidomide with rituximab (R2) for adult patients with relapsed or refractory (R/R) FL. The R2 regimen offers a chemotherapy-free treatment that will become immediately accessible to patients with R/R FL.1

The Lymphoma Hub reported results from the phase III AUGMENT trial (NCT01938001) which led to the U.S. Food & Drug Administration (FDA) and European Medicines Agency (EMA) approval of R2 in adult patients with R/R FL. Take a look at the Lymphoma Hub’s coverage of the AUGMENT study, FDA approval and EMA approval of R2.

  1. Lenalidomide with rituximab for previously treated follicular lymphoma [ID1374]. https://www.nice.org.uk/guidance/gid-ta10323/documents/final-appraisal-determination-document. Issued; February 2020, [Accessed February 27, 2020]

More about...
AUGMENTFollicular lymphomaIndolent B-cell lymphomasLenalidomideRituximab

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
60 votes - 48 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox